- Home
- KALA vs UNCY Comparison
KALA vs UNCY Comparison
Compare KALA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- UNCY
- Stock Information
- Founded
- KALA 2009
- UNCY 2016
- Country
- KALA United States
- UNCY United States
- Employees
- KALA N/A
- UNCY N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- UNCY Health Care
- Exchange
- KALA Nasdaq
- UNCY Nasdaq
- Market Cap
- KALA 27.7M
- UNCY 31.9M
- IPO Year
- KALA 2017
- UNCY 2021
- Fundamental
- Price
- KALA $5.31
- UNCY $0.36
- Analyst Decision
- KALA Strong Buy
- UNCY Strong Buy
- Analyst Count
- KALA 2
- UNCY 4
- Target Price
- KALA $16.50
- UNCY $5.13
- AVG Volume (30 Days)
- KALA 12.6K
- UNCY 1.5M
- Earning Date
- KALA 11-11-2024
- UNCY 11-12-2024
- Dividend Yield
- KALA N/A
- UNCY N/A
- EPS Growth
- KALA N/A
- UNCY N/A
- EPS
- KALA N/A
- UNCY N/A
- Revenue
- KALA N/A
- UNCY N/A
- Revenue This Year
- KALA N/A
- UNCY N/A
- Revenue Next Year
- KALA N/A
- UNCY N/A
- P/E Ratio
- KALA N/A
- UNCY N/A
- Revenue Growth
- KALA N/A
- UNCY N/A
- 52 Week Low
- KALA $4.21
- UNCY $0.20
- 52 Week High
- KALA $10.97
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- KALA 38.22
- UNCY 42.19
- Support Level
- KALA $5.25
- UNCY $0.35
- Resistance Level
- KALA $5.76
- UNCY $0.41
- Average True Range (ATR)
- KALA 0.23
- UNCY 0.04
- MACD
- KALA -0.01
- UNCY -0.01
- Stochastic Oscillator
- KALA 20.26
- UNCY 6.60
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.